II
CTMX icon

Inspire Investing’s CytomX Therapeutics CTMX Stock Holding History

Inspire Investing’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24 Hold
6
– – ﹤0.01% 1253
2026
Q1 		$30 Sell
6
-2
-25% -$10 ﹤0.01% 1086
2025
Q4 		$32 Sell
8
-522,474
-100% -$1.98M ﹤0.01% 1086
2025
Q3 		$1.67M Buy
+522,482
New +$1.18M 0.16% 145
2020
Q2 		– Sell
-53
Closed – – 550
2020
Q1 		$0 Buy
+53
New +$370 ﹤0.01% 753
2018
Q1 		– Sell
-58
Closed -$1K – 312
2017
Q4 		$1K Buy
+58
New +$1.2K ﹤0.01% 853

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Inspire Investing's CTMX Position: Q2 2026 in Review

Inspire Investing held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 6 shares worth $24. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

Inspire Investing first reported a position in CTMX in Q4 2017 and has held it in 6 quarters since. The position peaked at $1.67M in Q3 2025. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Inspire Investing held 6 shares of CytomX Therapeutics worth $24 as of Q2 2026.
  • Inspire Investing left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Inspire Investing's portfolio in Q2 2026, its #1253 holding.
  • Inspire Investing first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 6 quarters since.
  • Inspire Investing's CytomX Therapeutics position peaked at $1.67M in Q3 2025.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.